These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-001346-33 A Phase 3 Double-Blind Randomised, Placebo-Controlled Study of the safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2to <18) with Chronic Hepatitis B bad-data
Reported results 2004-002254-59 A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combi... 2007-06-25 due-trials
Completed, but no date, and reported results 2004-003745-40 Phase II pilot study on safety of administration of 3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment ( day 50-8th W... bad-data
Reported results 2004-005083-25 A Phase IV, Randomized, Double-Blind, Placebo-Controlled Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV 1 Seronegative Healthy Adult Males 2007-11-09 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-005119-27 A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B 2016-01-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-005120-41 A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B 2016-01-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-003136-22 A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combinatio... 2010-05-27 bad-data
Reported results 2005-004096-37 A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B... 2012-04-12 due-trials
Reported results Terminated 2005-004495-21 Pilot study on safety of four weekly administrations of 7 mg/kg of liposomal amphotericin B (AmBisome®) in antifungal primary prophylaxis treatment of elderly patients with acute lymphoblastic leukemi... 2007-08-17 due-trials
Ongoing, reported early 2005-004654-28 Phase IV, multicenter, randomized, open-label pilot study of Truvada or Emtricitabine alone versus HAART interruption in HIV-infected patients who need to interrupt HAART and who are infected with HIV... not-yet-due
Ongoing, reported early 2005-005786-11 Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from AZT containing backbone to Truvada in HIV-1-in... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2006-001898-25 DORADO-Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy a... 2009-01-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001899-20 DORADO-EX – A Dose-Blinded, Long Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension 2010-02-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003547-23 DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension 2009-08-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003548-42 DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension 2010-02-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-004714-40 A Randomized, Double Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B 2012-08-10 bad-data
Completed, but no date, and reported results 2007-000607-15 Phase II pilot multicenter study on efficacy and safety of liposomal amphotericin B (AmBisome) at 2 mg/kg/day in the treatment of candidemia and invasive candidiasis in nonneutropenic patients bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001601-16 A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects with C... 2009-03-31 bad-data
Reported results 2007-003354-28 A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching from a Stable HAART Regimen of fixed dose Abacavir/Lamivuidine (Kivexa) Plus Efavirenz, to Once D... 2010-01-12 due-trials
Reported results 2007-003418-32 A Phase III, Randomised, Open- Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate versus Continuing Stavudine or Zidovudine in Virologi... 2009-03-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-003704-35 A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection 2015-12-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004225-26 A multicenter, randomised, double-blind, double-dummy, phase III study of the safety and efficacy of Ritonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL) each administered with a background... 2015-04-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004277-26 An open-label, randomised, phase 3 trial to evaluate the efficacy and safety of Aztreonan LYsine for inhalation versus Tobramycin nebuliser solution in an intermittent aerosolized antibiotic regimen i... 2010-11-22 bad-data
Reported results 2007-005769-36 A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovir D... 2010-12-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-001464-36 A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofov... 2015-02-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-002043-16 A phase 4, open label, randomised, controlled study to assess the effect on lipid profile of switching a stable HAART regimen of fixed dose Kivexa + Kaletra to Truvada + Kaletra in adult HIV-1 infecte... 2009-10-19 bad-data
Exempt, with results 2008-002045-23 A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects. 2008-10-28 not-yet-due
Ongoing, reported early 2008-002361-31 A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults with Non-Alcoholic Steatohepat... not-yet-due
Reported results Terminated 2008-003839-20 A Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 µg Regadenoson Bolus for Pharmacological Stress Echocardiography 2010-06-04 due-trials
Reported results 2008-003917-29 A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents 2010-07-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-004405-34 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in subjects with Early Idiopathic Pulmonary... 2010-12-22 bad-data
Reported results 2008-004527-31 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ri... 2013-09-05 due-trials
Reported results Terminated 2008-007455-26 A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension 2012-01-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-007456-96 A Phase 2b, Double blind, Randomized, Parallel Group, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults with Chronic Hepatitis C Virus Infection 2010-04-20 bad-data
Reported results Terminated 2009-011169-98 A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmon... 2011-01-06 due-trials
Reported results 2009-013442-86 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with... 2010-12-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-013690-18 A Phase 2, Randomized, Open-Label trial of GS-9256 plus GS-9190 alone and in combination with Ribavirin for 28 days in Treatment Naive Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. 2012-01-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-016758-42 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine... 2014-10-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-016759-22 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoprox... 2015-04-16 bad-data
Reported results 2009-017168-17 A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction 2011-02-08 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019562-91 A Phase 3, Double-Blind, Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome) for the Prevention of Inv... 2014-01-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-020911-35 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in... 2013-08-16 bad-data
Reported results 2010-021925-12 FINITE CHB - First investigation in stopping TDF treatment after long term virologic suppression in HBeAg-negative Chronic Hepatitis B 2016-08-23 due-trials
Reported results 2010-022155-33 A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non- Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents 2018-05-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-023178-37 A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Ril... 2014-12-22 bad-data
Reported results Terminated 2010-023952-10 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) ... 2013-08-15 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-023959-28 A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of 2013-07-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-024007-27 A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen... 2014-02-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-024586-45 A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon ?-2a (Pegasys®) ver... 2015-07-17 bad-data
Reported results 2011-000456-42 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS 5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatmen... 2013-06-14 due-trials
Reported results 2011-000488-29 A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients with Mild to Moderate Renal Impairment 2015-02-16 due-trials
Completed, but no date, and reported results 2011-000944-43 A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection bad-data
Reported results 2011-000945-19 A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection 2017-11-30 due-trials
Reported results 2011-000946-39 A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection 2018-04-09 due-trials
Reported results 2011-000997-77 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects with Type 2 Diabetes Mellitus 2013-08-29 due-trials
Reported results 2011-001134-42 A phase 2, proof of concept, randomised, placebo-controlled, parallel group study to evaluate the effect of ranolazine and dronedarone when given alone and in combination on atrial fibrillation burden... 2014-03-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-001255-36 Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of 2013-06-20 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-001362-18 Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children with Cystic Fibrosis (CF) and Chronic ... 2013-04-03 bad-data
Reported results 2011-001516-54 A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging. 2012-09-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-002273-29 A Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects with Chronic Stable Angina and Coronary Artery Disease with a History of Type 2 Diabetes Mellitus 2012-10-24 bad-data
Reported results 2011-002507-15 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous ... 2015-02-09 due-trials
Reported results 2011-002748-28 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects w... 2013-07-29 due-trials
Reported results 2011-002931-25 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects with Type 2 Diabetes Mellitus 2013-10-21 due-trials
Reported results 2011-003753-26 A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma 2015-02-11 due-trials
Reported results Terminated 2011-003754-61 A Phase 2 Randomized, Double-Blind, Placebo-Controlled 2015-01-22 due-trials
Reported results 2011-004420-35 A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects 2014-10-06 due-trials
Reported results 2011-004483-30 A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to... 2014-12-16 due-trials
Reported results 2011-004963-56 A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to th... 2014-12-01 due-trials
Ongoing, reported early 2011-005055-14 A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in... not-yet-due
Reported results 2011-005180-24 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia 2014-05-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-006292-20 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymp... 2019-06-28 bad-data
Reported results 2011-006293-72 A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS-1101 (CAL 101) as Therapy for Patients with Previously Treated Chronic Lympho... 2018-06-29 due-trials
Reported results 2012-000571-16 An Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection who Participated in Prior Studies Evaluating GS-7977. 2014-12-22 due-trials
Completed, but no date Terminated 2012-000586-20 A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection bad-data
Completed, but no date, and reported results 2012-000637-39 An Open-Label Study to Explore the Clinical Efficacy of GS-7977 with Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant bad-data
Reported results 2012-001236-65 A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia 2018-08-15 due-trials
Reported results 2012-001259-37 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects with Type 2 Diabetes Mellitus. 2013-10-01 due-trials
Reported results Terminated 2012-001571-36 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) 2016-02-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-001942-16 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subje... 2014-01-08 bad-data
Reported results 2012-002413-19 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected with Respiratory Syncytial Virus (RSV-A Memph... 2013-06-27 due-trials
Reported results 2012-002417-19 A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 weeks in Subjects with Recurrent Chronic HCV Post Liver Transplant 2014-08-20 due-trials
Completed, but no date, and reported results 2012-002457-29 A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 24 weeks in Patients Infected with Chronic HCV with Cirrhosis and ... bad-data
Listed as ongoing, but also has a completion date and reported results 2012-002473-61 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with ... 2016-08-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-002488-88 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with... 2016-12-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-002489-11 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with... 2017-01-03 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-003387-43 A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects wit... 2014-04-30 bad-data
Ongoing 2012-003655-11 A multicenter, open-label, long-term follow-up safety and efficacy study of GLPG0634 treatment in subjects with moderately to severely active rheumatoid arthritis not-yet-due
Reported results 2012-003708-11 A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... 2018-09-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-004013-13 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymph... 2016-06-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-004034-42 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent ... 2016-05-17 bad-data
Reported results 2012-004154-28 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infe... 2014-07-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-004458-27 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Diso... 2017-09-29 bad-data
Completed, report not yet due 2012-005114-20 A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subj... 2020-04-01 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-000102-37 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Diso... 2018-10-03 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-000516-25 A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment 2018-07-18 bad-data
Ongoing 2013-000626-63 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Ne... not-yet-due
Ongoing, reported early 2013-000636-10 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Po... not-yet-due
Other 2013-001402-28 A Phase 2/3, Multicenter, Open-label, Multicohort, Two-Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/... not-yet-due
Reported results 2013-001969-16 A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) ... 2017-10-27 due-trials
Ongoing, reported early 2013-002296-17 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks with Ribavirin or for 24 ... not-yet-due
Reported results 2013-002641-11 A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or ... 2016-07-07 due-trials
Listed as ongoing, but also has a completion date 2013-002707-33 A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocyth... 2019-05-02 bad-data
Reported results 2013-002802-30 A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have ... 2015-08-27 due-trials
Reported results 2013-002830-19 A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafena... 2017-07-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-002897-30 A Phase 2b Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects with Renal Insufficiency 2017-10-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-003313-17 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocyt... 2016-06-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-003314-41 A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion 2016-05-16 bad-data
Ongoing, reported early 2013-003978-27 A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genot... not-yet-due
Reported results Terminated 2013-004105-11 A Phase 2, Open-label, Randomized Study to Evaluate Safety and Efficacy of Momelotinib in Subjects with Polycythemia Vera or Essential Thrombocythemia 2015-05-01 due-trials
Reported results 2013-004429-97 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy 2017-02-17 due-trials
Reported results 2013-004430-15 A Phase 2, Double-Blind, Randomized, Placebo Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibr... 2016-10-14 due-trials
Reported results 2013-004476-36 Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects with Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, Post essential Thrombocythemia Myelofibrosis,... 2018-12-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-004551-20 A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untre... 2016-05-13 bad-data
Not reported 2013-005007-13 A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosi... 2019-04-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-005138-39 A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF 2019-03-01 bad-data
Reported results 2013-005343-82 An Expanded Access Protocol for Idelalisib in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia 2017-08-15 due-trials
Reported results Terminated 2014-000042-30 A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT-3 Syndrome 2017-02-15 due-trials
Completed, but no date, and reported results 2014-001011-39 A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B an... bad-data
Reported results 2014-001245-24 An open-Label, multicenter study to evaluate the efficacy and safety of sofosbuvir/ledipasvir fixed-dose combination ± ribavirin for 12 or 24 weeks in chronic genotype 1 HCV infected subjects who part... 2015-11-12 due-trials
Other 2014-001249-26 A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Spo... not-yet-due
Ongoing, reported early 2014-001400-22 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects with Chronic Hepatitis B not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-001682-27 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects... 2015-11-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-001683-35 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV 2015-09-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-002095-93 A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus... 2016-02-17 bad-data
Reported results 2014-002121-35 A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients with Chronic H... 2016-06-16 due-trials
Reported results 2014-002131-34 A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension 2016-12-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-002137-58 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory ... 2017-04-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-002283-32 A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infecti... 2018-09-13 bad-data
Reported results 2014-002474-36 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) R... 2017-07-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-002475-29 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) R... 2017-04-17 bad-data
Reported results 2014-003578-17 A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- RBV in Adolescents and Children with Chronic HCV-Infec... 2018-08-24 due-trials
Reported results 2014-003898-42 An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection 2016-06-15 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-004480-20 A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with 2017-04-10 bad-data
Reported results 2014-004545-27 A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Su... 2019-01-09 due-trials
Other 2014-004674-42 A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead Sponsored Chronic Hepatitis C Infection Trials not-yet-due
Reported results 2014-004779-21 A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtric... 2019-01-02 due-trials
Reported results 2014-004812-12 Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Subjects with Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chro... 2016-01-08 due-trials
Reported results 2014-004939-39 Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicit... 2018-04-18 due-trials
Reported results 2014-005217-24 A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerat... 2016-11-16 due-trials
Other 2015-000366-66 Dose Optimization Study of Idelalisib in Follicular Lymphoma not-yet-due
Reported results 2015-000690-13 A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults with Chronic HCV Infection. 2016-06-30 due-trials
Reported results 2015-000871-28 A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC 2019-03-13 due-trials
Completed, but no date, and reported results Terminated 2015-001050-16 A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects with Chronic Hepatitis B Infection. bad-data
Reported results 2015-001249-10 A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Crohn’s Disease 2016-12-22 due-trials
Other 2015-001339-19 A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Re... not-yet-due
Reported results 2015-001526-42 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroes... 2019-05-15 due-trials
Reported results 2015-002017-30 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of ... 2019-05-03 due-trials
Reported results 2015-002192-23 A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects with Cystic Fibrosis 2017-07-21 due-trials
Reported results 2015-002287-16 A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) Infection 2017-09-27 due-trials
Reported results 2015-002710-74 A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infect... 2019-07-11 due-trials
Reported results 2015-002711-15 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Antiretroviral Agent to the Elvitegravi... 2018-01-24 due-trials
Reported results 2015-002712-32 A Phase 3b, Randomized, Open-Label Study to Evaluate Switching from a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF)... 2018-03-21 due-trials
Reported results 2015-002713-30 A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis 2019-10-15 due-trials
Reported results 2015-002731-17 A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (ENTO) combined with Vincristine (VCR) and VCR-based Combination Chemotherapy in Adult... 2017-06-22 due-trials
Reported results 2015-002768-18 A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refracto... 2018-12-17 due-trials
Reported results 2015-002996-12 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for ... 2017-01-02 due-trials
Reported results 2015-003001-42 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) infection 2017-09-13 due-trials
Reported results 2015-003167-10 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for... 2017-01-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2015-003455-21 A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direc... 2017-06-21 bad-data
Reported results 2015-003460-36 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatas... 2017-01-11 due-trials
Exempt, with results 2015-003741-26 A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-5829 as a Single Agent and In Combination with Enzalutamide in Subjects with Metastatic Castrate-Re... 2019-09-03 not-yet-due
Ongoing 2015-003909-42 A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib with and without Obinutuzumab in Subjects with Ch... not-yet-due
Other 2015-003988-10 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected... not-yet-due
Completed, reported early 2015-004011-20 A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lam... 2019-12-23 not-yet-due
Other 2015-004024-54 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral T... not-yet-due
Reported results 2015-004025-14 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9... 2019-10-23 due-trials
Reported results Terminated 2015-004572-30 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First... 2017-12-14 due-trials
Reported results 2015-005766-39 An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3Kδ Inhibitor, GS-9820 2017-12-28 due-trials
Reported results 2016-000416-15 A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have Received a Liver Transplan... 2017-07-28 due-trials
Reported results 2016-000417-73 A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects... 2017-10-27 due-trials
Reported results 2016-000568-41 A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Sub... 2019-06-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2016-000569-21 A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-... 2018-06-26 bad-data
Reported results 2016-000570-37 A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexa... 2019-05-08 due-trials
Ongoing 2016-000785-37 A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescents Subjects with Chronic Hepatitis B Virus Infecti... not-yet-due
Reported results 2016-000821-37 A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepa... 2018-05-25 due-trials
Reported results 2016-000897-39 Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects with Moderate to Severe Rheumatoid Arthritis. 2017-08-07 due-trials
Other 2016-001367-36 Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Sev... not-yet-due
Listed as ongoing, but also has a completion date 2016-001392-78 Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to ... 2020-03-31 bad-data
Other 2016-001399-31 A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men a... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2016-001402-41 A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesopha... 2019-08-23 bad-data
Reported results 2016-001496-75 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects with Active Rheumatoid Arthritis on Ba... 2017-09-20 due-trials
Exempt, with results 2016-002365-63 A Phase 1b Study Followed by an Open label, Parallel, Randomized Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of GS-5829 in Combination with Exemestane or Fulvestrant Comparing with ... 2018-07-19 not-yet-due
Completed, reported early 2016-002442-23 A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis 2020-05-18 not-yet-due
Reported results 2016-002443-42 A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis 2019-09-04 due-trials
Completed, reported early 2016-002446-23 A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection 2020-02-26 not-yet-due
Reported results 2016-002496-10 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH) 2018-01-09 due-trials
Ongoing 2016-002749-42 Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (A... not-yet-due
Other 2016-002763-34 A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease not-yet-due
Other 2016-002765-58 A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis not-yet-due
Completed, report not yet due 2016-002768-15 A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib with and without Obinutuzumab in Subjects with ... 2020-10-01 not-yet-due
Reported results 2016-003066-10 A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection and Chil... 2018-12-12 due-trials
Ongoing 2016-003153-15 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease not-yet-due
Listed as ongoing, but also has a completion date 2016-003179-23 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD) 2020-07-20 bad-data
Reported results 2016-003353-16 A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML) 2019-02-21 due-trials
Exempt 2016-003408-29 A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma not-yet-due
Reported results 2016-003489-25 A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Re... 2019-02-13 due-trials
Reported results 2016-003558-34 A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren’s Syndrome 2019-10-02 due-trials
Reported results 2016-003625-42 A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Disea... 2018-11-07 due-trials
Ongoing 2016-003630-25 A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis not-yet-due
Completed, reported early 2016-003632-20 A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Ch... 2020-01-30 not-yet-due
Reported results 2016-004148-13 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) 2019-04-30 due-trials
Reported results 2016-004374-18 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. 2019-06-12 due-trials
Completed, report not yet due 2016-004625-16 A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Viro... 2020-09-04 not-yet-due
Reported results 2017-000179-98 An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects who Participated in a Prior Gilead-Sponsored HCV Treatmen... 2018-03-19 due-trials
Completed, but no date 2017-000308-17 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Diso... bad-data
Ongoing 2017-000402-38 A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease not-yet-due
Listed as ongoing, but also has a completion date 2017-001468-39 Phase 1b trial evaluating idelalisib in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma or mediastinal B-cell lymphoma in combination with RICE 2018-11-16 bad-data
Other 2017-001485-17 A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non-Infectious Uveitis not-yet-due
Reported results Terminated 2017-003055-30 Immune Response to Influenza Vaccine in Subjects with B-cell Malignancies Treated with Idelalisib 2019-10-09 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003428-61 A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate Co... 2020-05-29 bad-data
Completed, reported early 2018-000480-87 A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed Dose Combination in Adolescents and Childre... 2020-02-19 not-yet-due
Ongoing 2018-000926-79 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir... not-yet-due
Listed as ongoing, but also has a completion date 2018-003951-39 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disea... 2020-01-06 bad-data
Other 2019-000204-14 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis not-yet-due
Ongoing 2019-001430-33 A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis not-yet-due
Ongoing 2019-001996-35 A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic DMA... not-yet-due
Other 2019-002021-29 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intol... not-yet-due
Ongoing 2019-003814-16 A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HI... not-yet-due
Completed, reported early 2020-000841-15 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 2020-06-30 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2020-000842-32 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment 2020-06-26 bad-data
Ongoing 2020-001453-49 Expanded Access Treatment Protocol: Remdesivir (RDV;GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection- COVID-19 not-yet-due
Other 2020-001803-17 A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19 not-yet-due
Other 2020-003510-12 A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting not-yet-due